|
Report No. : |
343832 |
|
Report Date : |
08.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
NEUTRO PHARMA (PVT.) LIMITED |
|
|
|
|
Registered Office : |
9.5 K.M., Sheikhupura Road, Lahore |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
2002 |
|
|
|
|
Com. Reg. No.: |
0044741 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Engaged in import, manufacture &
marketing of Pharmaceuticals & Neutraceutical Medicines |
|
|
|
|
No. of Employees : |
77 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Pakistan |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
NEUTRO PHARMA (PVT.) LIMITED
|
Registered
Address & Factory |
|
9.5 K.M., Sheikhupura Road, Lahore,
Pakistan |
|
Tel No. |
92 (42) 37915786, 37915787 |
|
Fax No. |
92 (42) 37915791 |
|
Website |
|
a. |
Nature of Business |
Engaged in import, manufacture &
marketing of Pharmaceuticals & Neutraceutical Medicines |
|
b. |
Year Established |
2002 |
|
c. |
Registration No. |
0044741 |
|
In Karachi &
Rawalpindi |
|
Arshad & Co. (Chartered Accountants) 102-Nawab Plaza,
48-Main Shadman Market, Lahore, Pakistan |
|
Subject Company
was established as a Private Limited Company in 2002 |
|
6. |
Authorized Capital |
Rs. 10,000,000/- divided into 100,000
shares of Rs. 100/- each |
|
|
Issued & Paid up Capital |
Rs. 10,000,000/- divided into 100,000
shares of Rs.100/- each |
|
Names |
Designation |
|
Mr. Zia-Ud-Din Zia Mr. Hamid Raza Mrs. Amir Raza |
Chief Executive Director Director |
|
Names |
No. of Shares |
|
Mr. Hamid Raza Mr. Amir Raza Mr. Zia-Ud-Din Zia |
84,000 15,000 1,000 |
|
(1) Shaf Pharmaceuticals, Pakistan. (2) Adnan Traders, Pakistan. (3) Darex Pharma, Pakistan. |
Engaged in import, manufacture &
marketing of Pharmaceuticals & Neutraceutical Medicines
77
|
The capacity and production of the
company’s plant is indeterminable as it is multi-product and involves various
processes of manufacture |
|
(1) PRINSEN B.V., HOLLAND. (2) SCHILLS FOOD, HOLLAND. (3) DONGKOO PHARMACEUTICALS CO., LTD,
KOREA. (4) DIA HAN PHARMACEUTICALS CO., LTD,
KOREA. (5) UNIMED PHARMACEUTICALS INCORPORATED,
KOREA (6) WAKAMOTO PHARMACEUTICALS CO. LTD,
JAPAN. (7) BOUCHARA RECORDITI, FRANCE. (8) I.C. PRODUCTS, SWITZERLAND. |
|
Year |
In Pak Rupees |
|
2013 |
130,000,000/- (Estimated) |
|
Major customers of the Company are
Distribution Companies, Private & Government Hospital’s |
|
(1) Habib Bank
Limited, Pakistan. (2) Bank Alfalah
Limited, Pakistan. (3) MCB Bank Limited,
Pakistan. (4) Allied Bank
Limited, Pakistan. |
Lahore Chamber of Commerce & Industry.
Pakistan Pharmaceutical Manufacturers Association.
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 104.25 |
|
UK Pound |
1 |
Rs. 157.90 |
|
Euro |
1 |
Rs. 116.25 |
Subject Company was established in 2002 and
is engaged in import, manufacture & marketing of Pharmaceuticals &
Neutraceutical Medicines. Overall reputation is normal. Trade relations are
reported as fair. Subject can be considered for normal business dealings at
usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.25 |
|
|
1 |
Rs.99.53 |
|
Euro |
1 |
Rs.73.47 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.